Benzinga · Feb 20, 2026
HC Wainwright & Co. Reiterates Buy on Dogwood Therapeutics, Maintains $12 Price Target
HC Wainwright & Co. analyst Sean Lee reiterates Dogwood Therapeutics (NASDAQ:DWTX) with a Buy and maintains $12 price target.
DW
NASDAQ · DWTX
Dogwood Therapeutics, Inc.
Healthcare · Biotechnology
$1.52
Up+$0.00 (+0.00%)
Updated Oct 6, 2026, 11:44 PM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 11.96M
- P/E ratio
- -0.31
- Dividend yield
- 0.00%
- 52-week range
- $1.28 – $7.30
- Volume
- 99.97K
- Avg. volume
- 758.26K
Price performance · DWTX
DWTX price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
DWTX closed at $1.52 after 20 trading sessions, down 25.49% for the selected period.
- Last close
- $1.52
- Period change
- -25.49%
- Period low
- $1.35
- Period high
- $2.04
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $1.50 | $1.72 | $1.45 | $1.52 | 99.97K |
| Oct 2, 2026 | $1.45 | $1.5599 | $1.43 | $1.46 | 71.09K |
| Oct 1, 2026 | $1.36 | $1.45 | $1.35 | $1.43 | 26.52K |
| Sep 30, 2026 | $1.35 | $1.39 | $1.32 | $1.35 | 34.38K |
| Sep 29, 2026 | $1.38 | $1.445 | $1.30 | $1.35 | 79.58K |
| Sep 28, 2026 | $1.40 | $1.46 | $1.35 | $1.36 | 82.07K |
| Sep 25, 2026 | $1.44 | $1.521 | $1.34 | $1.36 | 46.4K |
| Sep 24, 2026 | $1.51 | $1.555 | $1.42 | $1.43 | 17.17K |
| Sep 23, 2026 | $1.51 | $1.57 | $1.45 | $1.51 | 23.69K |
| Sep 22, 2026 | $1.63 | $1.7599 | $1.48 | $1.51 | 128.22K |
| Sep 21, 2026 | $1.67 | $1.73 | $1.58 | $1.60 | 61.68K |
| Sep 18, 2026 | $1.74 | $1.83 | $1.60 | $1.69 | 116.26K |
| Sep 17, 2026 | $1.80 | $1.80 | $1.70 | $1.72 | 48K |
| Sep 16, 2026 | $1.80 | $1.84 | $1.67 | $1.70 | 84.28K |
| Sep 15, 2026 | $1.81 | $1.84 | $1.72 | $1.73 | 31.86K |
| Sep 14, 2026 | $1.94 | $2.015 | $1.77 | $1.845 | 121.96K |
| Sep 11, 2026 | $1.88 | $2.00 | $1.83 | $1.94 | 53.08K |
| Sep 10, 2026 | $1.94 | $1.95 | $1.83 | $1.88 | 40.61K |
| Sep 9, 2026 | $2.125 | $2.15 | $1.895 | $1.94 | 39.26K |
| Sep 8, 2026 | $2.29 | $2.3438 | $2.04 | $2.04 | 85.89K |
Latest DWTX news
The latest Smart Investors Daily articles mentioning DWTX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
DWTX research
Overview
Company profile and research snapshot.
Company profile
Dogwood Therapeutics Inc, formerly Virios Therapeutics Inc, is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a virus-triggered abnormal immune response, such as fibromyalgia (FM) and long COVID (LC). Its product candidates include IMC-1 and IMC-2. IMC-1 is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 19, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 27, 2026 | HC Wainwright & Co. | Buy | — |
| Feb 20, 2026 | HC Wainwright & Co. | Buy | — |
| Jan 30, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 30, 2025 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Feb 2, 2026
DWTX: Financing Secures Funding Through Phase 2b Data Readout
By David Bautz, PhD NASDAQ:DWTX READ THE FULL DWTX RESEARCH REPORT Financial Update On January 15, 2026, Dogwood Therapeutics, Inc. (NASDAQ:DWTX) announced a securities purchase agreement with a single healthcare-focused institutional investor for up to approximately $12.5 million in gross proceeds through a registered direct offering and a concurrent private placement. An aggregate of 4,386,037
Yahoo · Feb 2, 2026
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026
- Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halneuron® treatment to be well tolerated - ATLANTA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced it has achieved over 50% of the planned enrollment in its ongoing HAL-CINP-203 Phase 2b chemotherapy induced neuropathic pain (“HALT-CINP”) trial.
Benzinga · Feb 2, 2026
Dogwood Reaches 50% Enrollment In Ongoing Halneuron Phase 2b Trial
- Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halneuron® treatment to be well tolerated -
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
